{
    "root": "6ae034de-c538-d33b-bd8a-65e229a6bcc7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ticagrelor",
    "value": "20241111",
    "ingredients": [
        {
            "name": "TICAGRELOR",
            "code": "GLH0314RVC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68558"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "Croscarmellose Sodium",
            "code": "M28OL1HH48"
        },
        {
            "name": "Isomalt",
            "code": "S870P55O2W",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_150326"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "Polyethylene Glycol 8000",
            "code": "Q662QK8M3B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "Powdered Cellulose",
            "code": "SMD1X3XO9M"
        },
        {
            "name": "Talc",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "Titanium Dioxide",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "Ferric Oxide Yellow",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "ticagrelor tablets p2y 12 platelet inhibitor indicated reduce risk cardiovascular ( cv ) death , myocardial infarction ( myocardial infarction ) , stroke patients acute coronary syndrome ( acs ) history myocardial infarction . least first 12 months following acs , superior clopidogrel . ticagrelor tablets also reduces risk stent thrombosis patients stented treatment acs . ( 1.1 ) reduce risk first myocardial infarction stroke patients coronary artery disease ( cad ) high risk events . limited setting , efficacy ticagrelor tablets established population type 2 diabetes mellitus ( t2dm ) . ( 1.2 ) reduce risk stroke patients acute ischemic stroke ( nih stroke scale score \u22645 ) high-risk transient ischemic attack ( tia ) . ( 1.3 )",
        "doid_entities": [
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "thrombosis (DOID:0060903)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060903"
            },
            {
                "text": "coronary artery disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "artery disease (DOID:0050828)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050828"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "type 2 diabetes mellitus (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            },
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            },
            {
                "text": "transient ischemic attack (DOID:224)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_224"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute ischemic stroke",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_439175"
            },
            {
                "disease": "acute coronary syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_454831"
            }
        ]
    },
    "contraindications": {
        "text": "acs history myocardial infarction initiate treatment 180 mg oral loading dose ticagrelor tablets . administer 90 mg twice daily first year . one year , administer 60 mg twice daily . ( 2.2 ) patients cad prior stroke myocardial infarction administer 60 mg ticagrelor tablets twice daily . ( 2.3 ) acute ischemic stroke initiate treatment 180 mg loading dose ticagrelor tablets continue 90 mg twice daily 30 days . ( 2.4 ) ticagrelor tablets daily maintenance dose aspirin 75 100 mg. ( 2 ) however , patients undergone pci , consider single antiplatelet therapy ticagrelor tablets based evolving risk thrombotic versus bleeding events . ( 2.2 )",
        "doid_entities": [
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute ischemic stroke",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_439175"
            }
        ]
    },
    "warningsAndPrecautions": "ticagrelor tablets 90 mg supplied yellow , round , biconvex , film-coated tablet . engraved \u201c apo \u201d one side \u201c \u201d \u201c 90 \u201d side . bottles 60 \u2013 ndc 60505-4452-6 storage handling store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "history intracranial hemorrhage . ( 4.1 ) active pathological bleeding . ( 4.2 ) hypersensitivity ticagrelor component product . ( 4.3 )",
    "indications_original": "Ticagrelor tablets are\u00a0a\u00a0P2Y 12 platelet\u00a0inhibitor indicated to\u00a0reduce the\u00a0risk\u00a0of\u00a0cardiovascular\u00a0(CV)\u00a0death,\u00a0myocardial\u00a0infarction\u00a0(MI),\u00a0and stroke in patients with acute coronary syndrome (ACS) or a history of\u00a0MI. For at least the first 12 months following ACS, it is superior to\u00a0clopidogrel. Ticagrelor tablets\u00a0also\u00a0reduces\u00a0the\u00a0risk\u00a0of\u00a0stent\u00a0thrombosis\u00a0in\u00a0patients\u00a0who\u00a0have\u00a0been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery\u00a0disease (CAD)\u00a0at\u00a0high\u00a0risk\u00a0for\u00a0such\u00a0events. While\u00a0use\u00a0is\u00a0not\u00a0limited to\u00a0this\u00a0setting, the efficacy of ticagrelor tablets were established in a population with\u00a0type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH\u00a0Stroke\u00a0Scale\u00a0score\u00a0\u22645)\u00a0or\u00a0high-risk\u00a0transient ischemic\u00a0attack\u00a0(TIA). (1.3)",
    "contraindications_original": "ACS\u00a0or\u00a0History\u00a0of\u00a0MI Initiate\u00a0treatment with\u00a0180\u00a0mg\u00a0oral\u00a0loading dose\u00a0of\u00a0ticagrelor tablets.\u00a0Then\u00a0administer 90 mg twice daily during the first year. After one year,\u00a0administer 60 mg twice daily. (2.2 ) Patients with CAD and No Prior Stroke or MI Administer\u00a060\u00a0mg\u00a0ticagrelor tablets\u00a0twice\u00a0daily. (2.3 ) Acute\u00a0Ischemic Stroke Initiate\u00a0treatment with\u00a0a\u00a0180\u00a0mg\u00a0loading dose\u00a0of\u00a0ticagrelor tablets\u00a0then\u00a0continue with 90 mg twice daily for up to 30 days. (2.4) Use\u00a0ticagrelor tablets\u00a0with\u00a0a\u00a0daily\u00a0maintenance\u00a0dose\u00a0of\u00a0aspirin of\u00a075 to 100\u00a0mg. (2 ) However, in patients who have undergone PCI, consider single antiplatelet therapy with ticagrelor tablets based on the evolving risk for thrombotic versus bleeding events. ( 2.2 )",
    "warningsAndPrecautions_original": "Ticagrelor tablets\u00a090\u00a0mg\u00a0are\u00a0supplied as\u00a0yellow, round, biconvex, film-coated tablet. Engraved \u201cAPO\u201d on one side and \u201cT\u201d over \u201c90\u201d on the other side. \u00a0 \n                  Bottles\u00a0of\u00a060\u00a0\u2013\u00a0NDC 60505-4452-6 \u00a0 \n                  \n                     Storage\u00a0and\u00a0Handling \u00a0\n                  \n                   Store\u00a0at\u00a020\u00b0C to\u00a025\u00b0C\u00a0(68\u00b0F to 77\u00b0F);\u00a0excursions\u00a0permitted to\u00a015\u00b0C\u00a0to\u00a030\u00b0C\u00a0(59\u00b0F\u00a0to\u00a086\u00b0F)\u00a0[see\u00a0USP\u00a0Controlled\u00a0Room\u00a0Temperature].",
    "adverseReactions_original": "History\u00a0of\u00a0intracranial\u00a0hemorrhage. (4.1) Active\u00a0pathological\u00a0bleeding. (4.2) Hypersensitivity\u00a0to\u00a0ticagrelor\u00a0or\u00a0any\u00a0component of\u00a0the\u00a0product. (4.3 )",
    "drug": [
        {
            "name": "Ticagrelor",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68558"
        }
    ]
}